1. 421PEGFR mutation analysis for prospective patient (pt) selection in AURA3 Phase III trial of osimertinib vs platinum-pemetrexed (plt-pem) in pts with EGFR T790M positive advanced non-small cell lung cancer (NSCLC). (22nd November 2017) Authors: Akamatsu, H; Delmonte, A; John, T; Su, W-C; Lee, J-S; Chang, G-C; Huang, X; Jenkins, S; Dearden, S; Wu, Y-L Journal: Annals of oncology Issue: Volume 28(2017)Supplement 10 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗